A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Prior treatment

• Taking any prohibited medications
  • Other protocol-defined inclusion/exclusion criteria may apply

Other illness

• Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia.
• History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study
• Transient ischemic attacks (TIA) or stroke occurring within 12 months
• Clinical evidence of liver or renal disease/injury
• Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis
• Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures
• Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes

Other

• Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening

• Male or female participants 50 to 85 years of age
• Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD
• Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0
• Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging
• Reliable study partner who can accompany the participant at study visits
• If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment